Article

Vision enhancement system facilitates safe phaco with decreased energy

The internal controls and responsiveness to changes in vacuum with a new vision enhancement system (Stellaris, Bausch & Lomb) have made high-vacuum, coaxial microincision cataract surgery a safe and efficient procedure, according to Elizabeth Davis, MD. The system also helps to decrease the amount of excess energy added to the eye beyond what is needed to remove a cataract.

The internal controls and responsiveness to changes in vacuum with a new vision enhancementsystem (Stellaris, Bausch & Lomb) have made high-vacuum, coaxial microincision cataract surgerya safe and efficient procedure, according to Elizabeth Davis, MD. The system also helps todecrease the amount of excess energy added to the eye beyond what is needed to remove acataract.

"With the interest in small-incision cataract surgery, the procedure produces less astigmatism,intraoperative safety is enhanced, and risk of infection is decreased," said Dr. Davis, who isaffiliated with the University of Minnesota, Minneapolis.

Many surgeons prefer to use ultrasound energy for a cataract procedure to avoid the chance ofcatastrophic loss of chamber stability and integrity that can occur when working with extremelyhigh levels of vacuum, she explained.

Dr. Davis and her colleagues evaluated 50 patients (mean age, 67.4 years) who underwentmodified supracapsular, high-vacuum technique with the system's vacuum module performed througha 1.8-mm incision. Next-generation fluidics (EQFluidics, Bausch & Lomb) allow for the use ofsmaller incisions and offer enhanced technology from the previous generation phaco system(Millennium, Bausch & Lomb).

The outcomes indicated that "vacuum up to 600 mm Hg can be used without surge or loss ofanterior chamber stability," Dr. Davis said. "There has been no clogging of the tubing[StableChamber, Bausch & Lomb], and the procedures have been extremely efficient. With vacuumset at 600 mm Hg, average phaco power use ranged from 0% to 4%."

Cataract densities ranged from 1 to 3+. In 94% of patients the mean phaco power was 0%, and in82% of patients the surgical time ranged from 4 to 8 minutes, she reported. The mean phacopower was 0.3% (range, 0 to 9%) and the mean phaco time was 0.22 seconds (range, 0 to 4seconds). The mean surgical time from incision to wound closure was 6.6 minutes (range, 3 to 11minutes). Denser cataracts required a longer surgical time. Corneas in 98% of patients wereclear.

Dr. Davis concluded that the transition to sub-2-mm surgery was accomplished withoutdifficulty, there was no change in surgical efficiency, and the operating room personnel foundthe system easy to use.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.